title: Effectiveness of H1N1/09 monovalent and trivalent influenza vaccines against hospitalization with laboratory-confirmed H1N1/09 influenza in Australia: a test-negative case control study.
abstract: We aimed to estimate the effectiveness of H1N1/09 containing influenza vaccines against hospitalization from influenza in Australia. We performed a test-negative case control study in patients hospitalized in 15 sentinel Australian hospitals between March and November 2010, comparing influenza vaccination (H1N1/09 monovalent or 2010 seasonal trivalent) in hospitalized patients with PCR-confirmed influenza compared to PCR-negative controls. Between March and November 2010, 1169 hospitalized patients were tested for suspected influenza, of which influenza vaccine status was ascertained in 165/238 patients with H1N1/09 influenza, 40/64 with seasonal influenza and 558/867 test negative controls; 24% of H1N1/09 cases, 43% of seasonal influenza cases and 54% of controls were vaccinated. VE against hospitalisation with H1N1/09 influenza after adjusting for age, medical comorbidities and pregnancy status was estimated at 49% (95% CI: 13%, 70%). Influenza vaccination was associated with a reduction in hospitalisation caused by H1N1/09 influenza in the 2010 southern hemisphere winter season.
authors.affiliation: Monash University, Australia. allen.cheng@monash.edu
authors.forename: Allen C
authors.initials: AC
authors.lastname: Cheng
authors.forename: Tom
authors.initials: T
authors.lastname: Kotsimbos
authors.forename: Heath A
authors.initials: HA
authors.lastname: Kelly
authors.forename: Louis B
authors.initials: LB
authors.lastname: Irving
authors.forename: Simon D
authors.initials: SD
authors.lastname: Bowler
authors.forename: Simon G A
authors.initials: SG
authors.lastname: Brown
authors.forename: Mark
authors.initials: M
authors.lastname: Holmes
authors.forename: Christine R
authors.initials: CR
authors.lastname: Jenkins
authors.forename: Philip
authors.initials: P
authors.lastname: Thompson
authors.forename: Graham
authors.initials: G
authors.lastname: Simpson
authors.forename: Richard
authors.initials: R
authors.lastname: Wood-Baker
authors.forename: Sanjaya N
authors.initials: SN
authors.lastname: Senanayake
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Brady
authors.forename: David L
authors.initials: DL
authors.lastname: Paterson
authors.forename: Peter A
authors.initials: PA
authors.lastname: Wark
authors.forename: John W
authors.initials: JW
authors.lastname: Upham
authors.forename: Tony M
authors.initials: TM
authors.lastname: Korman
authors.forename: Dominic E
authors.initials: DE
authors.lastname: Dwyer
authors.forename: Grant W
authors.initials: GW
authors.lastname: Waterer
authors.forename: Paul M
authors.initials: PM
authors.lastname: Kelly
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001315:Australia; D016022:Case-Control Studies; D002648:Child; D005260:Female; D006760:Hospitalization; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D007252:Influenza Vaccines